Domov › Vnetna črevesna bolezen › New York
Klinične študije za Vnetna črevesna bolezen v New York
21 študij za Vnetna črevesna bolezen išče udeležence na lokacijah v New York.
Mesta v New York
Uradno besedilo študije (angleško)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Ellipsis Research Group, Brooklyn
- Smart Medical Research - Jackson Heights, Jackson Heights
- Pioneer Clinical Research NY, New York
- in še 1
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06598943Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Albany
- Xencor Investigative Site, Rochester
Vključevanje udeležencevFaza 1/2Vabljeni zdravi prostovoljci
Starost 18–75 · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06619990A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 037, New York
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-002, Albany
- Site US-016, Rochester
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07845487A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05923073Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- in še 1
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT03816345A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Icahn School of Medicine at Mount Sinai, New York
Vključevanje udeležencevFaza 3
Starost 2–19 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT04844606A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
- Digestive Disease Medicine of Central New York, Utica
Vključevanje udeležencevFaza 4
3 Weeks · Ženske · Posodobljeno 8. sep. 2026 · NCT07612267A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05509777Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
- Weill Cornell Medicine, New York
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT06274554BOOM-IBD2 Pivotal Clinical Trial
- Northwell Health North Shore University Hospital, Manhasset
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Vključevanje udeležencev
Starost 18–85 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06571669Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- New York University, New York
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT07237516Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore Hutchinson Campus, The Bronx
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06266663Low Dose IL-2 for the Treatment of Crohn's Disease
- Mount Sinai, New York
Vključevanje udeležencevFaza 1/2
Starost 12–80 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT04263831Autologous Stem Cell Transplant for Crohn's Disease
- Icahn School of Medicine at Mount Sinai, New York
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 24. jul. 2026 · NCT03219359Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cohen Children's Medical Center of NY, Lake Success
- Columbia University Medical Center, New York
Vključevanje udeležencevFaza 4
Starost 6–17 · Vsi spoli · Posodobljeno 27. maj 2026 · NCT05781152Impact of Morning Light Therapy in IBD
- Mount Sinai Hospital, New York
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT07207200A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, New York
- Mirador Therapeutics Selected Site, Rochester
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT07113522Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
- NYU Langone Health, New York
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 5. mar. 2026 · NCT06309017Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
- Icahn School of Medicine at Mount Sinai, New York
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 7. jan. 2026 · NCT06001450Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- New York University, New York
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 8. maj 2025 · NCT06750731Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.